ChondroGene Gets Conditional OK to Trade on Toronto Exchange; Will Change Name to GeneNews | GenomeWeb
NEW YORK (GenomeWeb News) – ChondroGene today said it has received “conditional approval” from Canadian regulators to list its common shares on the Toronto Stock Exchange.
 
The company, which must still file final documentation, said it expects to begin trading its common shares on the TSX by Oct. 31.
 
At that time ChondroGene will change its name to GeneNews and will trade under the symbol GEN, and ChondroGene’s common shares will cease trading on the TSX Venture Exchange.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.